Mechanisms of Drug Resistance and Cancer Stem Cells

Czech version

Authors: J. Holčáková; M. Nekulová; P. Orzol; B. Vojtěšek
Authors‘ workplace: Regionální centrum aplikované molekulární onkologie, Masarykův onkologický ústav, Brno
Published in: Klin Onkol 2014; 27(Supplementum): 34-41

Overview

Although the success of anticancer treatments has been increasing annually, drug resistance remains the dominant cause of death of cancer patients. Initial therapy often leaves residual disease that leads to repeated tumor development or to loss of its sensitivity to available therapy. One reason of residual disease formation is the presence of cancer stem cells (CSCs). CSCs have been identified as a small population of cells that is capable of self‑ renewal and differentiation. It is supposed that these cells are responsible for cancer initiation, progression, metastasis, recurrence and drug resistance. Over the past years, much attention has been paid to development of CSCs‑related therapies and to identification of key molecules involved in controlling the specific properties of CSCs populations. This article reviews the basic mechanisms of drug resistance in relation to cancer stem cells.

Key words:
drug resistance − cancer stem cells − membrane transport proteins – epithelial-mesenchymal transition – tumor microenvironment − apoptosis

This work was supported by research program of the Internal Grant Agency, Ministry of Health of the Czech Republic: NT/14602 – 3/2013, by the European Regional Development Fund and the State Budget of the Czech Republic (RECAMO CZ.1.05/2.1.00/03.0101) and by Ministry of Health, Czech Republic − conceptual development of research organization (MMCI, 00209805).

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Submitted:
3. 2. 2014

Accepted:
7. 5. 2014

Sources

1. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11(4): 265– 283.

2. Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 2000; 65(1): 95– 106.

3. Provenzano PP, Cuevas C, Chang AE et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 21(3): 418– 429. doi: 10.1016/ j.ccr.2012.01.007.

4. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21(3): 309– 322. doi: 10.1016/ j.ccr.2012.02.022.

5. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6(5): 392– 401.

6. Feig C, Gopinathan A, Neesse A et al. The pancreas cancer microenvironment. Clin Cancer Res 2012; 18(16): 4266– 4276. doi: 10.1158/ 1078- 0432.CCR‑ 11-3114.

7. Calabrese C, Poppleton H, Kocak M et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11(1): 69– 82.

8. Kees T, Egeblad M. Innate immune cells in breast can-cer – from villains to heroes? J Mammary Gland Biol Neoplasia 2011; 16(3): 189– 203. doi: 10.1007/ s10911- 011- 9224- 2.

9. Konopleva M, Tabe Y, Zeng Z et al. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat 2009; 12(4– 5): 103– 113. doi: 10.1016/ j.drup.2009.06.001.

10. Sternlicht MD, Lochter A, Sympson CJ et al. The stromal proteinase MMP3/ stromelysin‑1 promotes mammary carcinogenesis. Cell 1999; 98(2): 137– 146.

11. Sutherland RM, Eddy HA, Bareham B et al. Resistance to adriamycin in multicellular spheroids. Int J Radiat Oncol Biol Phys 1979; 5(8): 1225– 1230.

12. Trédan O, Galmarini CM, Patel K et al. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99(19): 1441– 1454.

13. Sethi T, Rintoul RC, Moore SM et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999; 5(6): 662– 668.

14. Mori Y, Shimizu N, Dallas M et al. Anti‑alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 2004; 104(7): 2149– 2154.

15. Park CC, Zhang H, Pallavicini M et al. Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 2006; 66(3): 1526– 1535.

16. Shain KH, Landowski TH, Dalton WS. Adhesion‑ mediated intracellular redistribution of c‑ Fas‑associated death domain‑like IL‑1‑converting enzyme‑like inhibitory protein‑long confers resistance to CD95‑induced apoptosis in hematopoietic cancer cell lines. J Immunol 2002; 168(5): 2544– 2553.

17. Hazlehurst LA, Enkemann SA, Beam CA et al. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res 2003; 63(22): 7900– 7906.

18. Sandal T, Valyi‑ Nagy K, Spencer VA et al. Epigenetic reversion of breast carcinoma phenotype is accompanied by changes in DNA sequestration as measured by AluI restriction enzyme. Am J Pathol 2007; 170(5): 1739– 1749.

19. Jones CB, McIntosh J, Huang H et al. Regulation of bleomycin‑induced DNA breakage and chromatin structure in lung endothelial cells by integrins and poly(ADP‑ ribose) polymerase. Mol Pharmacol 2001; 59(1): 69– 75.

20. Hay ED. An overview of epithelio‑ mesenchymal transformation. Acta Anat (Basel) 1995; 154(1): 8– 20.

21. Kalluri R, Neilson EG. Epithelial‑ mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112(12): 1776– 1784.

22. Lee JM, Dedhar S, Kalluri R et al. The epithelial‑ mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006; 172(7): 973– 981.

23. Thiery JP. Epithelial‑ mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2(6): 442– 454.

24. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29(34): 4741– 4751. doi: 10.1038/ onc.2010.215

25. Chiba N, Comaills V, Shiotani B et al. Homeobox B9 induces epithelial‑ to‑ mesenchymal transition‑associated radioresistance by accelerating DNA damage responses. Proc Natl Acad Sci USA 2012; 109(8): 2760– 2765. doi: 10.1073/ pnas.1018867108.

26. Harris AL. Hypoxia – a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2(1): 38– 47.

27. Semenza GL. Hypoxia and cancer. Cancer Metastasis Rev 2007; 26(2): 223– 224.

28. Wirthner R, Wrann S, Balamurugan K et al. Impaired DNA double‑strand break repair contributes to chemoresistance in HIF‑ 1 alpha‑ deficient mouse embryonic fibroblasts. Carcinogenesis 2008; 29(12): 2306– 2316. doi: 10.1093/ carcin/ bgn231.

29. Choi YJ, Rho JK, Lee SJ et al. HIF‑ 1alpha modulation by topoisomerase inhibitors in non‑small cell lung cancer cell lines. J Cancer Res Clin Oncol 2009; 135(8): 1047– 1053. doi: 10.1007/ s00432- 009- 0543-2.

30. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455(1): 152– 162.

31. Szakacs G, Paterson JK, Ludwig JA et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5(3): 219– 234.

32. Haimeur A, Conseil G, Deeley RG et al. The MRP‑related and BCRP/ ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 2004; 5(1): 21– 53.

33. Plati J, Bucur O, Khosravi‑ Far R. Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb) 2011; 3(4): 279– 296. doi: 10.1039/ c0ib00144a.

34. Wei Y, Fan T, Yu M. Inhibitor of apoptosis proteins and apoptosis. Acta Biochim Biophys Sin (Shanghai) 2008; 40(4): 278– 288.

35. Lanneau D, Brunet M, Frisan E et al. Heat shock proteins: essential proteins for apoptosis regulation. J Cell Mol Med 2008; 12(3): 743– 761. doi: 10.1111/ j.1582- 4934.2008.00273.x.

36. Fulda S. Evasion of apoptosis as a cellular stress response in cancer. Int J Cell Biol 2010; 2010: 370835. doi: 10.1155/ 2010/ 370835.

37. Stewart DJ, Chiritescu G, Dahrouge S et al. Chemotherapy dose – response relationships in non‑small cell lung cancer and implied resistance mechanisms. Cancer Treat Rev 2007; 33(2): 101– 137.

38. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358(11): 1148– 1159. doi: 10.1056/ NEJMra072067.

39. Tsai HC, Li H, Van Neste L et al. Transient low doses of DNA‑ demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012; 21(3): 430– 446. doi: 10.1016/ j.ccr.2011.12.029.

40. Sharma SV, Lee DY, Li B et al. A chromatin‑mediated reversible drug‑tolerant state in cancer cell subpopulations. Cell 2010; 141(1): 69– 80. doi: 10.1016/ j.cell.2010.02.027.

41. Hauswald S, Duque‑ Afonso J, Wagner MM et al. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin Cancer Res 2009; 15(11): 3705– 3715. doi: 10.1158/ 1078-0432.CCR‑ 08- 2048.

42. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI‑ 571 cancer therapy caused by BCR‑ ABL gene mutation or amplification. Science 2001; 293(5531): 876– 880.

43. Carter TA, Wodicka LM, Shah NP et al. Inhibition of drug‑resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005; 102(31): 11011– 11016.

44. Kaiser J. Combining targeted drugs to stop resistant tumors. Science 2011; 331(6024): 1542– 1545. doi: 10.1126/ science.331.6024.1542.

45. Duy C, Hurtz C, Shojaee S et al. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR‑ ABL1 kinase inhibition. Nature 2011; 473(7347): 384– 388. doi: 10.1038/ nature09883.

46. Essers MA, Trumpp A. Targeting leukemic stem cells by breaking their dormancy. Mol Oncol 2010; 4(5): 443– 450. doi: 10.1016/ j.molonc.2010.06.001

47. Saito Y, Uchida N, Tanaka S et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol 2010; 28(3): 275– 280. doi: 10.1038/ nbt.1607.

48. Jiang X, Zhao Y, Smith C et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR‑ ABL targeted therapies. Leukemia 2007; 21(5): 926– 935.

49. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3(7): 730– 737.

50. Al‑ Hajj M, Wicha MS, Benito‑ Hernandez A et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100(7): 3983– 3988.

51. Kim CF, Jackson EL, Woolfenden AE et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005; 121(6): 823– 835.

52. O‘Brien CA, Pollett A, Gallinger S et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445(7123): 106– 110.

53. Collins AT, Berry PA, Hyde C et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65(23): 10946– 10951.

54. Szotek PP, Pieretti‑ Vanmarcke R, Masiakos PT et al. Ovarian cancer side population defines cells with stem cell‑like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA 2006; 103(30): 11154– 11159.

55. Piccirillo SG, Reynolds BA, Zanetti N et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour‑ initiating cells. Nature 2006; 444(7120): 761– 765.

56. Fang D, Nguyen TK, Leishear K et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65(20): 9328– 9337.

57. Jordan CT. Cancer stem cells: controversial or just misunderstood? Cell Stem Cell 2009; 4(3): 203– 205. doi: 10.1016/ j.stem.2009.02.003.

58. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011; 17(3): 313– 319. doi: 10.1038/ nm.2304.

59. Reya T, Morrison SJ, Clarke MF et al. Stem cells, cancer, and cancer stem cells. Nature 2001; 414(6859): 105– 111.

60. Adams JM, Strasser A. Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res 2008; 68(11): 4018– 4021. doi: 10.1158/ 0008- 5472.CAN‑ 07- 6334.

61. Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012; 22(3): 457– 472. doi: 10.1038/ cr.2012.13.

62. Campbell LL, Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle 2007; 6(19): 2332– 2338.

63. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 2010; 1805(1): 105– 117. doi: 10.1016/ j.bbcan.2009.11.002.

64. Shackleton M, Vaillant F, Simpson KJ et al. Generation of a functional mammary gland from a single stem cell. Nature 2006; 439(7072): 84– 88.

65. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8(10): 755– 768. doi: 10.1038/ nrc2499.

66. Deeley RG, Westlake C, Cole SP. Transmembrane transport of endo‑ and xenobiotics by mammalian ATP‑binding cassette multidrug resistance proteins. Physiol Rev 2006; 86(3): 849– 899.

67. Baguley BC. Multiple drug resistance mechanisms in cancer. Mol Biotechnol 2010; 46(3): 308– 316. doi: 10.1007/ s12033- 010-9321- 2.

68. Aguirre‑Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7(11): 834– 846.

69. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444(7120): 756– 760.

70. Diehn M, Cho RW, Lobo NA et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009; 458(7239): 780– 783. doi: 10.1038/ nature07733.

71. Guo G, Qiu X, Wang S et al. Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v‑ Abl‑ mediated pre‑B‑ cell transformation and survival of Pim‑ deficient cells. Oncogene 2010; 29(26): 3845– 3853. doi: 10.1038/ onc.2010.149.

72. Gutierrez A, Sanda T, Grebliunaite R et al. High frequency of PTEN, PI3K, and AKT abnormalities in T‑ cell acute lymphoblastic leukemia. Blood 2009; 114(3): 647– 650. doi: 10.1182/ blood‑ 2009-02- 206722.

73. Qiu X, Guo G, Chen K et al. A requirement for SOCS‑ 1 and SOCS‑ 3 phosphorylation in Bcr‑ Abl‑induced tumorigenesis. Neoplasia 2012; 14(6): 547– 558.

74. Baud V, Karin M. Is NF‑ kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009; 8(1): 33– 40. doi: 10.1038/ nrd2781.

75. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation and cancer. Cell 2010; 140(6): 883– 899. doi: 10.1016/ j.cell.2010.01.025.

76. Chaturvedi MM, Sung B, Yadav VR et al. NF‑ kappaB addiction and its role in cancer: ‚one size does not fit all‘. Oncogene 2011; 30(14): 1615– 1630. doi: 10.1038/ onc.2010.566.

77. Dontu G, Jackson KW, McNicholas E et al. Role of notch signaling in cell‑ fate determination of human mammary stem/ progenitor cells. Breast Cancer Res 2004; 6(6): R605– R615.

78. Williams RF, Sims TL, Tracey L et al. Maturation of tumor vasculature by interferon‑beta disrupts the vascular niche of glioma stem cells. Anticancer Res 2010; 30(9): 3301– 3308.

79. Deng YH, Pu XX, Huang MJ et al. 5- Fluorouracil upregulates the activity of wnt signaling pathway in CD133- positive colon cancer stem‑like cells. Chin J Cancer 2010; 29(9): 810– 815.

80. Merchant AA, Matsui W. Targeting Hedgehog – a cancer stem cell pathway. Clin Cancer Res 2010; 16(12): 3130– 3140. doi: 10.1158/ 1078- 0432.CCR‑ 09-- 2846.

81. Kobune M, Takimoto R, Murase K et al. Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells. Cancer Sci 2009; 100(5): 948– 955. doi: 10.1111/ j.1349– 7006.2009.01111.x.

82. Malanchi I, Peinado H, Kassen D et al. Cutaneous cancer stem cell maintenance is dependent on beta‑catenin signalling. Nature 2008; 452(7187): 650– 653. doi: 10.1038/ nature06835.

83. Zeng YA, Nusse R. Wnt proteins are self‑ renewal factors for mammary stem cells and promote their long‑term expansion in culture. Cell Stem Cell 2010; 6(6): 568– 577. doi: 10.1016/ j.stem.2010.03.020.

84. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005; 434(7035): 843– 850.

85. Teng Y, Wang X, Wang Y et al. Wnt/ beta‑catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem Biophys Res Commun 2010; 392(3): 373– 379. doi: 10.1016/ j.bbrc.2010.01.028.

86. Schatton T, Frank NY, Frank MH. Identification and targeting of cancer stem cells. Bioessays 2009; 31(10): 1038– 1049. doi: 10.1002/ bies.200900058.

87. Zhou BB, Zhang H, Damelin M et al. Tumour‑ initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009; 8(10): 806– 823. doi: 10.1038/ nrd2137.

88. Curiel TJ. Immunotherapy: a useful strategy to help combat multidrug resistance. Drug Resist Updat 2012; 15(1– 2): 106– 113. doi: 10.1016/ j.drup.2012.03.003.

89. Tsuruo T, Iida H, Tsukagoshi S et al. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41(5): 1967– 1972.

90. Khdair A, Chen D, Patil Y et al. Nanoparticle‑ mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. J Control Release 2010; 141(2): 137– 144. doi: 10.1016/ j.jconrel.2009.09.004.

91. Sims‑ Mourtada J, Izzo JG, Ajani J et al. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene 2007; 26(38): 5674– 5679.

92. Li K, Li Y, Wu W et al. Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3. J Biol Chem 2008; 283(12): 8046– 8054. doi: 10.1074/ jbc.M800170200.

93. He B, Reguart N, You L et al. Blockade of Wnt‑ 1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 2005; 24(18): 3054– 3058.

94. Ramaswamy B, Lu Y, Teng KY et al. Hedgehog signaling is a novel therapeutic target in tamoxifen‑resistant breast cancer aberrantly activated by PI3K/ AKT pathway. Cancer Res 2012; 72(19): 5048– 5059. doi: 10.1158/ 0008- 5472.CAN‑ 12- 1248.

95. Feldmann G, Habbe N, Dhara S et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 2008; 57(10): 1420– 1430. doi: 10.1136/ gut.2007.148189.

96. Fan L, Li F, Zhang H et al. Co‑ delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance. Biomaterials 2010; 31(21): 5634– 5642. doi: 10.1016/ j.biomaterials.2010.03.066.

97. Ganta S, Amiji M. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 2009; 6(3): 928– 939. doi: 10.1021/ mp800240j.

98. Kang MH, Reynolds CP. Bcl‑ 2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15(4): 1126– 1132. doi: 10.1158/ 1078- 0432.CCR‑ 08-0144.

99. Burkhardt JK, Hofstetter CP, Santillan A et al. Orthotopic glioblastoma stem‑like cell xenograft model in mice to evaluate intra‑ arterial delivery of bevacizumab: from bedside to bench. J Clin Neurosci 2012; 19(11): 1568– 1572. doi: 10.1016/ j.jocn.2012.03.012.

100. Folkins C, Man S, Xu P et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem‑like cell fraction in glioma xenograft tumors. Cancer Res 2007; 67(8): 3560– 3564.

101. Lee ES, Gao Z, Kim D et al. Super pH‑ sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance. J Control Release 2008; 129(3): 228– 236. doi: 10.1016/ j.jconrel.2008.04.024.